Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 50Stomach Neoplasms 13Colonic Neoplasms 5Rectal Neoplasms 4Sarcoma 3Neoplasms 2Neoplasm Metastasis 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1TAS 102 1Sarcoma, Ewing 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Locally Advanced Rectal Cancer 1HER2-positive Gastric Cancer 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Colorectal Adenocarcinoma 1Carcinoma, Renal Cell 1

Interventions

regorafenib 1Programmed Cell Death 1 Receptor 1Irinotecan 1Immune Checkpoint Inhibitors 1IFL protocol 1HMPL-013 1Folfox protocol 1Cetuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Colorectal Adenocarcinoma × HMPL-013 × Clear all
NCT07130903 2025-11-10

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
102 enrolled
Gastrointestinal

Metastatic Colorectal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡